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Abstract 
 
AZD6738 is an orally active ATR inhibitor (ATRi) currently in phase I clinical trials.  We found in vitro 
growth inhibitory activity of this ATRi in a panel of human cancer cell lines.  We demonstrated 
radiosensitization by AZD6738 to single radiation fractions in multiple cancer cell lines independent 
of both p53 and BRCA2 status by clonogenic assay. Radiosensitization by AZD6738 to clinically-
relevant doses of fractionated radiation was demonstrated in vitro using a 3D tumor spheroid model 
and, in vivo, AZD6738 radiosensitized by abrogating the radiation-induced G2 cell cycle checkpoint 
and inhibiting homologous recombination. Mitosis with damaged DNA resulted in mitotic catastrophe 
as measured by micronucleus formation by live cell fluorescent-ubiquitination cell cycle imaging of 
cell cycle progression and nuclear morphology. Induction of micronuclei was significantly more 
prominent for AZD6738 compared to inhibition of the downstream kinase CHK1 alone at isoeffective 
doses. Micronuclei were characterized as acentric chromosomal fragments which displayed 
characteristics of increased DNA damage and cell cycle dyssynchrony when compared to the primary 
nucleus. 
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Introduction 
 
There is a need for tumor-selective radiosensitizers to increase tumor control without increasing 
normal tissue toxicities. Numerous novel agents have demonstrated promising pre-clinical activity in 
this context but few have progressed beyond the earliest stages of clinical development (1). 
 
Most tumor cells have a defective G1 checkpoint (2), leaving the G2 checkpoint critical for cell cycle 
arrest and DNA repair following damage. The G2 checkpoint, through its principal effectors ATR and 
Chk1, is an attractive target for selective sensitization of cancer cells(3).  Normal cells have an intact 
G1 checkpoint, rendering them less sensitive to G2 checkpoint abrogation.  
 
Ionizing radiation causes a variety of DNA lesions: direct double-strand breaks (DSB), one-ended 
secondary DSB as a result of collapsed replication forks, single-strand breaks (SSB), base and sugar 
damage, and intra-strand crosslinks. ATR is one of the principal kinases of the DNA damage response 
(DDR). It is activated through lesions which result in expanses of single-stranded DNA (ssDNA) which 
become coated with replication protein A, leading to binding and activation of ATR through its partner 
ATRIP. The most well-described ATR target is Chk1, which effects cell cycle arrest at the intra-S and 
G2 checkpoints. Chk1 inhibitors have been shown to radiosensitize in pre-clinical studies (4). ATR 
also targets replication fork factors under normal and perturbed DNA replication(5), and DNA repair 
pathways including homologous recombination (HR), crosslink repair and nucleotide excision 
repair(6). ATR inhibition has been shown to potentiate DNA-damaging chemotherapy (platinum, 
gemcitabine)(7), and it has been proposed that ATR may be important for the radioresistance of 
hypoxic cells (8-10). 
 
ATR inhibitors (ATRi) (7) are currently in early phase clinical trials as monotherapy, in combination 
with DNA-damaging chemotherapy and radiotherapy and in combination with other novel agents 
(NCT02157792, NCT01955668, NCT02223923, NCT02264678). Here we demonstrate in vitro and in 
vivo radiosensitization by the orally active, specific ATR inhibitor AZD6738(11), which is in phase I 
clinical development. 
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Materials and Methods 
 
Cell Culture 
CAL27, FaDu , A549 (obtained 2013), PJ34, PJ41 (obtained 2014), T24 , A2780, RT4 ( obtained 2012), 
NCI-H1838 (2013), NCI-H1373 (2015), DU-4475 (year unknown, STR profiled 2016) cell lines were 
purchased from ATCC. SCC090 and SCC131 were purchased from DSMZ (Brunswick, Germany, 2014). 
SK-OV-3 (2011) was obtained from HPA culture collection (Porton Down, UK).  HCT116 p53 Xman 
isogenic cell lines were purchased from Horizon Discovery (Cambridge, UK, 2014), DLD1 BRCA2 wild-
type and deficient cells were provided to the ICR as part of a collaborative agreement. HT-29-luc2 was 
purchased from Caliper (Hopkinton, US, 2015). LON-LICR-HN4, LON-LICR-HN5 cell lines from 
Professor Sue Eccles (ICR, London, 2012).  STR profiling was carried out by Bio-Synthesis Inc. (Texas, 
US). Mycoplasma testing used the e-Myco PCR kit (Intron Biotechnology, South Korea).  Cell lines 
received from non-commercial sources were STR profiled prior to freezing, all cell lines were 
mycoplasma tested, and experiments carried out within 3 months of resuscitation. 
 
Drugs and Irradiation 
AZD6738 (12) was obtained from AstraZeneca. The ATM inhibitor KU-55933 (13) was obtained from 
Stratech Scientific Ltd (Suffolk, UK). CCT244747 (14) was obtained from Professor Ian Collins (The 
Institute of Cancer Research, UK). Irradiation was carried out using an AGO 250 kV X-ray machine 
(AGO, Reading, UK).  
 
MTT, Clonogenic and Spheroid Assay 
Cells were seeded in 96-well plates, drugged the following day, viability was determined at 72 h by 
MTT assay.  Absorbance at 550 nm was measured and normalized to DMSO-treated cells. For 
clonogenic assays, cells were seeded at appropriate densities and left overnight.  Drug was added 1 h 
before, and removed 48 h after irradiation. Colonies were fixed in 5% glutaraldehyde-0.5% crystal 
violet. Counting was performed both manually or automated using CellProfiler or GelCount (Oxford 
Optronix, Oxford, UK). Colony counts expressed as surviving fraction relative to plating efficiency of 
DMSO only treated control. Curves were corrected for drug only toxicity and the enhancement ratio 
estimated by linear quadratic curve fitting using ܻ = ݁ି(ఈ௑ା ఉ௑మ) and interpolating the radiation dose 
required to achieve a SF of 0.37 using GraphPad Prism 6 (GraphPad Software, San Diego, USA). For 
spheroid assays, cells were plated in ultra-low attachment plates (Corning, Kennebunk, USA).  After 1 
week, 20 Gy in ten daily fractions of 2 Gy was administered. Drug was added 1 hour prior to 
irradiation and replaced thrice weekly during irradiation.  Spheroids were imaged using a Celigo 
cytometer (Nexcelom, Lawrence, USA) and cross-sectional area assessed using CellProfiler(15). 
 
Immunoblotting 
Cells were scraped in PBS with 2 mM Na3VO4 and cell pellets lysed in 50 mM Tris.HCl pH 7.5, 150 mM 
NaCl, 1% NP-40, 0.5% deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 2 mM Na3VO4 and protease 
inhibitors. In vivo samples were processed by homogenization using a Precellys24 homogenizer 
(Bertin Technologies, Montigny, France). Protein supernatants, quantified by BCA assay (Pierce, 
Leicestershire, UK), were separated by SDS-PAGE, transferred to PVDF membrane (Thermo Scientific, 
Waltham, USA) and blocked in TBS with 5% non-fat dry milk and 0.1% Tween-20. Membranes were 
probed using the following antibodies: phospho-ATM Ser1981, #5883; ATM, #2873; p21 #2946; 
phospho-p53 Ser15, #2528; GAPDH, #2118; Chk1, #2360; phospho-Chk1 Ser345, #2341; Chk2,  
#2662; phospho-Chk2 Thr68, #2197; γH2AX, #9718; cleaved caspase 3, #9661 and cleaved PARP 
#5625, were all obtained from Cell Signalling (Danvers, USA). p53 DO-7 mAb #M7001 was obtained 
from Dako (Cambridge, UK) and PARP-1 from Santa Cruz Biotechnology (Dallas, USA).  For confocal 
microscopy on fixed cells, γH2AX JBW-301 (Merck-Millipore, Darmstadt, Germany) and Rad51 H-92 
(Santa Cruz 8349) were used. 
 
 5 
 
Flow Cytometry 
Cell cycle analysis: cells were fixed in ice-cold ethanol for at least 8 h, then rehydrated in PBS before 
staining in PBS with 1% BSA, 0.1% Tween-20, 0.5 mg/mL RNAse A and 10 µg/mL PI (Sigma). Mitotic 
index: cells were fixed in 10% formalin for 20 minutes, rinsed in PBS, blocked in 1% BSA in PBS for 15 
minutes and stained with phospho-S10 histone-H3 Alexa-647 (Cell Signaling) for 15-30 minutes.  DNA 
content and phospho-histone H3 positive cells were measured using an LSR II flow cytometer (BD 
Biosciences, Oxford, UK) 
 
Confocal Microscopy 
FFPE tissue antigen retrieval was performed at pH 6 in a pressure cooker.  Samples were treated with 
DNAse I (Roche) 1000 units/mL in PBS for 1 h at 37 degrees before washing in PBS, blocking in PBS 
with 1% BSA, 2% FBS.  Slides were stained for anti-Rad51 (GeneTex 70230) and anti-γH2AX (Cell 
Signaling) overnight at 4 degrees and incubated with fluorescent secondary antibodies, 
counterstained with DAPI, mounted in mounting medium (Dako S3023), coverslipped and sealed 
before imaging with Zeiss LSM710 inverted confocal microscope (Carl Zeiss, Jena, Germany). Images 
were acquired as z-stacks, processed as a maximum-intensity projection and quantified with a 
minimum of three fields of view with an average of 150 nuclei per field.  In vitro cells were left to 
attach overnight on35 mm glass bottom dishes (Mattek, Ashland, USA).  At the indicated time points, 
cells were fixed in 10% formalin and permeabilized with 0.2% Triton X-100 with blocking and 
staining as above.  Images were quantified using imageJ or CellProfiler. 
 
In Vivo xenografts 
All experiments were approved by the Institutional Review Board and complied with National Cancer 
Research Institute guidelines (16).  6-week old female NOD scid gamma (NSG) mice were obtained 
from Charles River (UK), 2 million HCT116 p53-/- were implanted subcutaneously.  When tumors 
reached approximately 5 mm diameter, animals were divided into 4 equal groups.  AZD6738 was 
administered at a dose of 75 mg/kg once daily by oral gavage, in 10% DMSO, 40% propylene glycol, 
50% water. Three orthogonal tumor diameters were measured by vernier calipers and volume 
calculated as V = π/6 d1·d2·d3.  The experimental endpoint was a tumor diameter of 15 mm. For 
hypoxia studies, pimonidazole (Hypoxyprobe, HPI, Burlington, USA) 60mg/kg was injected 
intraperitoneally 1 hour prior to collection. 
 
High content microscopy 
Cal27 cells were transfected with Fluorescent Ubiquitination-based Cell Cycle Indicator (FUCCI) cell 
cycle vectors pRetroX-G1-Red and pRetroX-SG2M according to manufacturer’s instructions using 
MMLV retrovirus and GP2-293 packaging cell line (Clontech, Mountain View, USA).  G1 red expresses 
mCherry hCdt1(30-120aa); S-G2M cyan expresses AmCyan hGeminin(1-110aa).  Cells were seeded in 
96-well optical plastic bottomed plates and imaged using an Operetta microscope (PerkinElmer, 
Waltham, USA).  Drug treatments were added 1 hour prior to irradiation and imaging started 
immediately after irradiation.  Data was collected every 15 minutes for 60 hours and analyzed using 
Columbus software (PerkinElmer). 
 
Comet assay 
Trypsinized cells were combined 1:8 with 1% low melting point agarose, placed onto a 1% normal 
melting point agarose pre-coated slide, coverslipped on ice for 5 minutes before lysis (NaCl 2.5M, 
EDTA disodium salt 100 mM and Tris base 10 mM in distilled water, adjusted to pH10.5 with NaOH, 
1% DMSO and 1% Triton X-100) for 1 hour at 4 degrees in the dark. Slides were placed in an 
electrophoresis tank with 300 mM NaOH, 1 mM EDTA and 1% DMSO for 30 mins before 
electrophoresis at 25V, 300mA, neutralized with 500mM Tris-HCl, pH 8.0; DNA was stained using 
SYBR-safe (ThermoFisher) and imaged using a Zeiss LSM710 confocal microscope.  A minimum of 115 
cells were analyzed from 2 independent replicates and percent tail DNA was calculated using 
OpenComet 1.3 plugin for ImageJ (17).   
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Statistical analyses 
Statistical analysis was performed using Prism 6. Means were compared using Student’s unpaired t-
test.  Individual cell data were compared using one way ANOVA with Tukey’s multiple comparisons 
test.  An asterisk indicates p <0.05. 
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Results 
 
AZD6738 single agent activity is p53-independent 
 
IC50 values for AZD6738 were calculated from 72h MTT dose-response curves (Fig. 1A). Sensitivity 
ranged from 0.52 μM for LoVo, a colorectal cancer cell line, to 5.32 μM for NCI-H1373, a lung cancer 
cell line. Evidence of apoptotic cell death by PARP cleavage was observed for cell lines throughout the 
sensitivity range (Fig. 1B). 
 
Dysfunctional p53 has previously been reported as a putative marker of sensitivity to ATR inhibition.  
We tested the panel for p53 functional status by probing for Ser15 phospho-p53, total-p53, and the 
downstream transcriptional target p21 after 4 Gy irradiation (supplementary Fig. 1).  No significant 
difference in sensitivity was observed between p53 functional and dysfunctional cell lines (Fig. 1C). 
To further investigate the effect of p53 status, the sensitivity of HCT116 cells with and without 
functional p53 was compared. Sensitivity to AZD6738 was similar across a range of concentrations 
(Fig. 1D). 
 
Radiosensitization by AZD6738 in vitro 
 
Clonogenic assays showed radiosensitization by AZD6738 in both p53 wild-type A549 (Fig. 2A), and 
p53 mutant Cal27 and FaDu cell lines (Fig. 2B; Fig. 2C). HCT116 cells were equally radiosensitized by 
AZD6738 irrespective of p53 status (Fig. 2D). Western analysis showed that radiation activates the 
ATR-Chk1 (as shown by phosphorylation of Chk1 on the ATR-specific S345 site) and ATM-Chk2 
pathways. AZD6738 inhibited radiation-induced Chk1 phosphorylation but had no impact on ATM-
Chk2 signaling (Fig. 2E). ATRi promoted mitotic entry following irradiation, as measured by the 
proportion of cells positive for phospho-histone H3 (Fig. 2F). Cell cycle analysis indicated abrogation 
of the radiation-induced G2 checkpoint by AZD6738 (Fig. 2G). To investigate the effect on fractionated 
treatment, tumor spheroids of FaDu and SCC7 (a murine squamous carcinoma cell line) were treated 
with 20 Gy in 10 fractions in the presence or absence of AZD6738.  Significant difference was seen 
between the radiation and radiation-ATRi curves (Fig. 2H, supplementary Fig. 2).  Bliss analysis for 
synergy between radiation and ATRi was calculated using the equation Eexp = Ex + Ey – (ExEy). Eexp is the 
expected effect if two treatments are additive with Ex and Ey corresponding to the effect of each treatment 
individually. ΔE = Eobserved - Eexp. Evidence of synergy was observed in both cell lines with ΔE ± 95% CI 
values of 0.22 ± 0.025 for FaDu and 0.234 ± 0.01 for SCC7, both at 21 days. 
 
Radiosensitization by AZD6738 in an in vivo model 
 
Mice bearing HCT116 p53 null xenograft tumors received 4 fractions of 2 Gy over 4 days, with vehicle 
or AZD6738 administered 2 hours before irradiation and for one day following irradiation (Fig. 3A). 
Radiation delayed tumor growth and combination of AZD6738 and radiation significantly delayed 
tumor growth compared with radiation alone (Fig. 3B) and significantly prolonged survival over 
vehicle control, AZD6738 alone and radiation alone (Fig. 3C). There were no deaths due to treatment-
related toxicity. Western analysis on tumor samples harvested 2 hours after the first dose of radiation 
confirmed drug-on-target effect in vivo, with reduction of radiation-induced S345Chk1 phosphorylation 
(Fig. 3D). 
 
AZD6738 enhances radiation induced DNA damage by reducing homologous recombination  
 
To investigate the effect of AZD6738 on radiation-induced DNA damage and repair, FFPE xenograft 
specimens were taken 4 hours after the final of 4 fractions of radiation with vehicle or AZD6738. 
Nuclei were probed for γH2AX and Rad51 foci by confocal microscopy. More γH2AX foci were 
observed when radiation was combined with AZD6738 with a corresponding decrease in RAD51 foci 
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(Fig. 4A; Fig. 4B). Variations in geminin staining indicate that the substantial reduction in Rad51 foci 
was partially due to cell cycle distribution (Fig. 4B). Rad51 and γH2AX foci were also quantified in oxic 
and hypoxic conditions using pimonidazole to identify these regions. As expected, fewer γH2AX foci 
were observed in hypoxic areas after radiation.  AZD6738 increased γH2AX foci in both oxic and 
hypoxic conditions (Fig. 4C). 
 
To assess DNA damage and repair kinetics, we analyzed in vitro response to single radiation fractions. 
Fewer γH2AX and RAD51 foci were observed 8 h post-radiation in combination with AZD6738 (Fig. 
4D, Fig. 4E, Fig. 4F).  Single cell analysis of Rad51 foci numbers at 8 and 24 h found that there were 
significantly fewer Rad51 foci in the combination group at 24 h after irradiation (Fig. 4E), as well as a 
greater proportion of cells without foci (supplementary Fig. 3). 
 
Due to the discrepancy seen between the γH2AX foci in in vivo fractionated and in vitro single fraction 
experiments, we hypothesized that reduced γH2AX at early time points after a single fraction could be 
due to reduction in ATR-mediated phosphorylation of H2AX(18) at these times, rather than a 
reflection of decreased DNA damage per se, with more γH2AX foci after fractionated radiation 
reflective of persistent DNA damage. We used the alkaline comet assay as a sensitive direct method to 
assess levels of unrepaired DNA damage. We found that a reduction in γH2AX due to AZD6738 at 8 h 
post-irradiation did not indicate a reduction in DNA damage, but that DNA damage present was 
marginally higher than radiation alone (Fig. 4G). Significantly more residual DNA damage was 
observed at 24 hours in the cells treated with AZD6738 and radiation compared to radiation alone. 
Together these results indicate that the combination treatment leads to increased DNA damage, but 
decreased repair signaling through γH2AX and HR. 
 
Abrogation of radiation induced G2 arrest by AZD6738 results in acentric chromosome 
fragments 
 
To determine the role of HR inhibition, AZD6738-mediated radiosensitization was assessed by 
clonogenic assay in a DLD1 BRCA2-/- isogenic cell line model. HR deficiency was confirmed by 
confocal microscopy (supplementary Fig. 4). Although the BRCA2 null cell line was extremely 
sensitive to radiation, it was still profoundly radiosensitized by the addition of AZD6738 (Fig. 5A). 
This strongly indicated that while loss of HR repair sensitizes to radiation, AZD6738 sensitization may 
be mediated by both inhibition of DNA repair and abrogation of the G2 checkpoint. 
 
To study the consequences of mitotic transition with unrepaired DNA damage due to AZD6738 we 
generated Cal27 FUCCI cells. These express mCherry hCdt1(30-120aa) in G1/S and AmCyan 
hGeminin(1-110aa) in S/G2M enabling discrimination of cell cycle progression and nuclear 
morphology (19).  Automated high content microscopy and image analysis software were used to 
quantify numbers of cells in each phase of the cell cycle over a 60 hour time course.  This showed that 
G2 arrest peaked 11 hours after radiation and that this was abrogated in the presence of AZD6738.  
There was a gradual accumulation of cells in S phase after treatment with radiation and AZD6738 
which may reflect higher numbers of stalled replication forks after irradiation in the presence of 
AZD6738 (Fig. 5B). 
 
Automated quantification of nuclear morphology revealed a sharp increase in micronuclei due to the 
combination of AZD6738 and radiation (Fig. 5C). This coincided with abrogation of the radiation 
induced G2 arrest (Fig. 5B). Prolonged exposure to AZD6738 also gave rise to a less pronounced 
increase in micronuclei. Timelapse microscopy showed cell death in mitosis or abnormal mitosis 
resulting in micronuclei and subsequent cell death in interphase (Fig. 5D). We also noted some 
micronuclei had increased levels of γH2AX compared to the main nucleus or dyssynchrony of cell 
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cycle phase (Fig. 5E). Death was apoptotic based on a morphology of cell blebbing and apoptotic 
bodies which was confirmed by increased cleaved PARP and cleaved caspase 3 (Fig. 5F). 
 
To further investigate the mechanism of micronucleus formation, we fixed cells at 24 hours and 
stained for the presence or absence of the centromere marker CENPA.  We found that in both Cal27 
and FaDu the majority of micronuclei were acentric chromosomal fragments lacking a centromere 
(Fig. 5G; Fig. 5H). These data confirmed significantly more micronuclei were present after 
combination treatment in both cell lines (Fig. 5G, Fig. 5H) cells. Greater numbers of micronuclei were 
observed when isoeffective (equal effects on monotherapy growth inhibition) doses of ATRi were 
used compared with Chk1 inhibitors, indicating a potentially different mechanism of 
radiosensitization between these two types of compound (Fig. 5I).  
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Discussion  
 
Through detailed mechanistic analysis both in vitro and using in-vivo xenograft specimens, we have 
demonstrated radiosensitization by AZD6738, in multiple cell lines, through reduced HR and 
abrogation of the radiation-induced G2 cell checkpoint, promoting an aberrant mitosis which results 
in acentric chromosome fragment-containing dysfunctional micronuclei, indicative of mitotic 
catastrophe.  We also found S-phase accumulation after AZD6738 and RT, suggestive of accumulating 
stalled replication forks.    Our studies have used clinically meaningful doses of 2 Gy and 4 Gy, 
commonly used in radical and palliative radiotherapy, respectively.  The radiosensitizing effect at 
these doses will be amplified over a course of radiotherapy which uses multiple 2-4 Gy fractions: we 
have shown significant enhancement of radiation tumor control with the addition of AZD6738 at 20 
Gy in 10 fractions, currently being assessed in a phase I study in an in vitro model, and delayed tumor 
growth in vivo.  The sensitizer enhancement ratios we have obtained would translate into a significant 
reduction in radiation dose required for tumor control (see supplementary table 1). 
 
ATRi monotherapy has been shown to be more effective when used in cell lines with defects in the 
DDR(20-24) or activated oncogenes(25,26), presumably due to the increased replication stress that 
these generate. In our panel of cell lines, a narrow sensitivity range was observed for AZD6738 alone, 
with evidence of death by apoptosis. Radiosensitization was uniformly observed in p53 wild-type, null 
and mutant as well as BRCA2 null cell lines. ATRi have been shown to sensitize to DNA-damaging 
chemotherapies, an effect which seems to be enhanced by p53 loss(27). The ability of ATRi to 
radiosensitize irrespective of p53 status has been reported previously(9), we confirm these findings 
in multiple cell lines and an isogenic paired model and also report that this lack of selectivity also 
applies to monotherapy ATRi – both these conclusions will be relevant for patient selection strategies 
in clinical trials. 
 
AZD6738 reduced HR after RT both in vitro and with fractioned RT in vivo. It has been suggested that 
there may be a contribution to radiation-induced DNA damage from replication fork stalling after 
single-strand DNA damage (28). Persistent DNA damage after irradiation due to reduced HR has been 
observed when ATR activity is reduced by knockdown (29). The observed reduction in γH2AX 
signaling at later timepoints after irradiation in vitro suggests a role for ATR in maintenance of DSB 
signaling, perhaps becoming activated by secondary DSB and replication stress as cells continue to 
replicate DNA after irradiation. However, after fractionated radiation in vivo, we observed increased 
numbers of γH2AX foci – this may reflect the difference between DSB repair kinetics in exponentially 
growing cells in vitro compared with an in vivo tumor subjected to fractionated radiation and 
variations in proliferation and oxygenation. 
 
Previous studies have shown that ATRi caused increased DNA damage under hypoxic conditions (9), 
possibly as a result of replication fork collapse (10).  We did not see a significant increase in γH2AX 
foci in hypoxic regions in the presence of AZD6738 alone, however in combination with fractionated 
radiation we observed persistent γH2AX foci in both oxygenated and hypoxic regions, suggesting that 
AZD6738 may enhance radiation damage in hypoxic areas. More γH2AX foci were apparent in oxic 
regions than hypoxic regions for both fractionated radiation and in combination with AZD6738. This 
is in keeping with previous observations on DNA damage and hypoxia. 
 
Use of a DLD1 BRCA2 null isogenic model revealed AZD6738 could still potently radiosensitize an 
already HR deficient, highly radiosensitive cell line. This suggests G2-checkpoint inhibitory activity is 
critical for radiosensitization and is likely to act in a combinatorial fashion with DNA repair inhibition 
by AZD6738. Live cell cycle imaging suggests that the downstream consequence of DNA damage 
repair inhibition and G2 checkpoint abrogation is a profound increase in chromosomal segregation 
errors. 
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Analysis revealed that AZD6738 combined with radiation produced daughter cells with micronuclei 
almost entirely comprising acentric chromosomal fragments. These fragments are likely to be highly 
heterogeneous and, consequently, the presence of micronuclei alone is not enough to predict cell 
death or survival.  However, they represent increased genomic instability and have been described as 
a hallmark of mitotic catastrophe. Hence, assessing their accumulation after drug-radiation 
combinations may represent a method of assessing radiosensitizing potential.  We have observed that, 
combined with radiation, ATRi generates more micronuclei than Chk1i.Micronuclei may represent a 
loss or a gain of chromosomal material, depending upon which daughter cell the micronucleus is 
transferred to. Whole chromosome or partial arm aneuploidy occurs at a high frequency in 
cancer(30). Micronuclei can persist for a number of mitoses or re-integrate into the primary nucleus 
resulting in increased genomic instability(31). 
 
Micronuclei have also been shown to be dysfunctional relative to the primary nucleus. We observed 
dyssynchrony between the main nucleus and micronuclei and γH2AX positive micronuclei following 
combination therapy with AZD6738 and radiation. Recent evidence has suggested micronuclei lack 
normal nuclear import function as well as being susceptible to rupturing of the micronuclei nuclear 
membrane. Micronuclei can be subject to reduced DNA replication and increased DNA damage due to 
replication leading to “pulverization” of the micronuclei(32). This matches our observation of cell 
cycle dyssynchrony  Further studying the lethality of theseradiosensitizer-induced chromosomal 
missegregation errors may allow maximization of the therapeutic gains from this approach. 
 
Conclusion 
 
This study demonstrates radiosensitization of a variety of cancer cell lines with different intrinsic 
radiosensitivities, and shows efficacy in vivo.  Given the synergy already demonstrated between ATR 
inhibition and platinum chemotherapy (27), this strongly supports the further development of this 
approach to investigate ATR inhibition in combination with radiation and chemoradiation in clinical 
studies. 
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Figure Legends 
 
Fig 1 
(A)Cell line IC50 values assessed for growth inhibition in a 72 h MTT assay. (B) Evidence of PARP 
cleavage (detected using antibody specific to the cleaved fragment) with ATRi monotherapy for 48h 
at 0. 5 μM AZD6738. (C) Cell line IC50 sorted by p53 functional status.  Differences between groups 
were compared using the Mann-Whitney test (D) Comparison of dose-response curves to AZD6738 
treatment of HCT116 p53 wild-type and HCT116 p53 null cells.  Dose-response curves were plotted 
based on 72 h MTT. Inset western blot represents assessment of p53 function by exposing to 
radiation.  
 
Fig 2 
(A) Radiosensitization of A549 cells by AZD6738 demonstrated by clonogenic assay. Number of 
colonies expressed as a fraction of the number on untreated plates.  Surviving fractions normalized 
to the cell kill by AZD6738 alone, expressed in the box on each graph. (B) Cal27cells, as per (A); (C) 
FaDu cells, as per (A).  (D) clonogenic assay demonstrating radiosensitization of HCT116 wild-type 
and p53-null cells by AZD6738. Clonogenic data were analyzed by ANOVA with multiple 
comparisons, * indicates p<0.05.  Minimum of 3 replicates, error bars represent SEM. SER:  sensitizer 
enhancement ratio obtained by fitting a linear quadratic curve and obtaining the ratio for sensitized 
and unsensitized conditions to achieve survival of 0.37. (E) Western blot for ATM, Chk1, Chk2 
function 1 h after 4 Gy in the presence or absence of AZD6738. (F) Cell cycle distribution effect of 
AZD6738 and radiation, propidium iodide flow cytometry.  Cells exposed to 0.5 μM AZD6738 or 
DMSO control, 1h prior to 4 Gy or mock irradiation, harvested 16 or 24 hours later. Percentage cell 
cycle distributions are displayed. (G) Cal27 cells were stained for mitotic fraction using phospho-
histone-H3. AZD6738 was added one hour prior to irradiation and cells harvested 6 hours after. 
Percentage of cells staining positive for phospho-histone-H3 are displayed.  Error bars: SEM. 
Minimum of 3 replicates. (H) Analysis of tumor spheroid growth for FaDu and SCC7 cells treated with 
AZD6738 (1 μM), fractionated radiation (20 Gy in 10 fractions over 2 weeks), or the combination.  
Drug was added 1 hour prior to radiation and removed after the final fraction of radiation.  
Spheroids were imaged weekly.  Error bars: SEM, 3 replicates; * indicates p<0.05 between RT only 
and RT-ATRi curves. 
 
Fig 3 
(A) Experimental schedule: NSG Mice bearing HCT116 p53-/- tumour xenografts.  N=9 control, 9 
AZD6738, 13 radiation only, 9 radiation + AZD6738.  (B)  Tumour growth curves, normalized to the 
first tumour measurement after treatment began. Error bars: SEM.  (C) Survival probabilities, p 
value: difference between radiation and radiation + AZD6738. (D) Western analysis of xenograft 
samples for p(S345)Chk1 after irradiation or mock irradiation in the presence or absence of 75 
mg/kg AZD6738 administered 2 hours prior to radiation treatment, samples collected 2 h after 
radiation. 
 
Fig 4 (A) Quantification of γH2AX (A) and Rad51 (B) foci in formalin-fixed, paraffin-embedded 
HCT116 (p53 null) xenograft tumors at the indicated timepoints after a fractionated course of 2 x 4 
Gy (daily fractions) given with vehicle or 75 mg/kg AZD6738 daily by oral gavage, 2 h prior to 
irradiation. (B) Representative images showing cells quantified in (A) and (B) scale bar represents 10 
μm; bottom row shows immunohistochemical staining with anti-geminin antibody of xenografts 
shown in (A). (C) Histograms of γH2AX foci distribution in oxic and hypoxic conditions (determined 
by pimonidazole staining) for radiation alone (4 x 2 Gy) and radiation + AZD6738, for formalin-fixed 
paraffin embedded specimens from the in vivo fractionated regimen used in (A) and (B). (D) 
Quantification of γH2AX foci at the indicated timepoints after a single fraction of 4 Gy in the 
presence or absence of 0.25 μM AZD6738 in Cal27 cells. A minimum of 3 high power fields were 
analyzed from each of 2 independent experiments, an average of 356 (range 174-653) cells per 
condition were analyzed. (E) Quantification of Rad51 foci per nucleus at 8 and 24 hours after 4 Gy in 
the presence or absence of 0.25 μM AZD6738.  Only Rad51 positive cells were quantified (average 
89.5 cells per condition, range 63-144).   (D, E) Data per cell presented, analyzed by one way ANOVA 
with multiple comparisons. Error bars: SEM. At least 2 independent experiments. (F) Representative 
images showing nuclear foci presented in (D) and (E), scale bar represents 1 μm. (G) Alkaline comet 
assay analysis for the indicated conditions. Cal27 cells were treated with drug or DMSO 1h prior to 
irradiation and lysed at the indicated timepoints before alkaline comet assay was performed.  Single 
cell data for percent tail DNA are presented, inset images are representative comets for each 
condition, line represents mean and error bars represent SD. Data from 2 independent experiments.  
 
Fig 5 
(A) Clonogenic survival assay comparing DLD1 cells with wild-type or absent BRCA2. Surviving 
fractions normalized to the cell kill by AZD6738 alone, expressed in the inset box.  Solid lines: wild 
type, interrupted lines: BRCA2 null. (B) Analysis of cell cycle distributions over a 60-hour time period 
following 4 Gy or mock irradiation in the presence of AZD6738 (0.9 μM, the IC50 value derived from 
72h MTT assay) or DMSO control.  Nuclei were automatically quantified and cell cycle phase 
assigned to each nucleus depending upon fluorescence. (C) Quantification of micronuclei (expressed 
as number of micronuclei counted divided by number of nuclei counted) over the timecourse.  
Points represent mean of 3 measurements and lines represent the smoothed mean. (D) 
Representative images from timelapse microscopy.  Upper panel shows a cell going through normal 
mitosis; middle panel shows the first mitosis yielding micronuclei, dyssynchrony of cell cycle 
between the micronucleus and nucleus and subsequent apoptosis at the second mitosis; lower panel 
shows a cell undergoing apoptosis at the first mitosis. (E) Representative images showing 
micronuclei with γH2AX staining (top panel) and representative images showing cell-cycle phase 
dyssynchrony between the main nuclei and micronuclei. (F) Western analysis showing levels of 
cleaved caspase 3 and cleaved PARP, reflective of apoptotic cell death, 24 hours after mock 
irradiation or 4 Gy in the presence of 0.25 μM AZD6738 or DMSO control in Cal27. (G) Quantification 
of fixed Cal27 and FaDu cells, 24 hours after mock irradiation or 4 Gy in the presence of 0.25 μM 
AZD6738 or DMSO control; box plots represent range, with line at median number of micronuclei 
per nucleus. (H) Proportion of micronuclei positive or negative for the kinetochore marker CENPA, 
treated with 4 Gy or 4 Gy in the presence of 0.25 μM AZD6738 in Cal27 (left) and FaDu (right).  
Images show representative nuclei and micronuclei showing absence of CENPA in micronuclei.  Scale 
bar represents 10 μm.  (I) Quantification of the average number of micronuclei over the 60-hour 
timecourse, in cells treated with AZD6738, the Chk1 inhibitor CCT244747 at isoeffective doses for 
single-agent growth inhibition (0.9 μM AZD6738, 1.3 μM CCT244747). 
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